That's what Rudolph Tanzi, a prominent Alzheimer's researcher at MGH says about the work of Robert Moir, a member of his team. A story in STAT last week -- which ran in today's Globe - chronicles Moir's struggle to get funding for a theory that Alzheimer’s disease is a triggered by microbes in the brain. "If true, the … Continue reading STAT: :Neuroinflammation is where we’re going to find [Alzheimer’s] drugs.”
Umass doc weights in on this. Also see research from Silent Spring Institute. AAP release here. From Times: “Because hormones act at low concentrations in our blood, it is not surprising that even low-level exposures to endocrine disrupters can contribute to disease,” said Laura N. Vandenberg, an assistant professor in the department of environmental health … Continue reading UMass doc comments on pediatricians statement re: plastic food containers
Ms. Marsa won't be here this week, but there will be a lot of talk on climate change. Monday Noon. "Methane: A Uniquely Difficult Greenhouse Gas Mitigation Problem." Robert Kleinberg. HKS: Bell Hall, Belfer Building. Details. Tuesday 1p. "Climate Change, Air Quality, and Human Health." Patrick Kinney. Harvard Global Health Institute, 42 Church St., Cambridge. Details, RSVP. … Continue reading Boston events, week of 3/19/18: Will climate change kill us? Find out this week.
You can't buy it yet, but marijuana is now legal under state law. For the latest on weed law and science, tune in Friday for a Harvard School of Public Health live webcast. Or, watch it via Facebook Live. Send panelists questions in advance to firstname.lastname@example.org Tweet us @ForumHSPH #marijuanascience
A recent story in The Atlantic asks "Is the Leading Theory About Alzheimer's Wrong?" For years, scientist have been arguing about whether amyloid protein in the brain is a cause,or just a symptom of condition. Pharma has been confident -- or desperate -- enough in the science to bet on amyloid clearing drugs, but they … Continue reading Selkoe to discuss #amyloid and #Alzheimer’s in wake of another disappointing drug study
Science in the News was started by Harvard students who wanted to help explain complex issues to the public. The group has expanded beyond that to events like: Tonight! Science by the Pint with The STAT Team The (sometimes messy) science of communicating science Monday, January 9, 6:30-8:30pm at The Burren (247 Elm Street, Somerville) … Continue reading Tonight! Meet the #STATnews team at The Burren pub in Somerville #science
My report from Health Leaders on a recent talk by members of Henrietta Lacks' family. The ongoing story of the late Henrietta Lacks, the African-American woman who unwittingly provided cells for years of medical research, has much to offer those battling disparities in healthcare, according to family members who spoke in Boston last week. That … Continue reading Health Leaders: #Lacks family members now have a say in #Henrietta’s immortal scientific legacy
Pharmaceutical manufacturers often look to patient advocates for help winning approval for new drugs. Their most recent success in this area was the FDA’s approval of a new drug for Duchenne muscular dystrophy. That decision came despite recommendations against approval from FDA staff. In an editorial, the Boston Globe questioned the FDA’s move while noting … Continue reading Two Boston meetings look at the role of patient advocates. They offer two very different perspectives.
The Globe reports today on the push to make an AIDS prevention drug available. After many years of struggling to come up with a vaccine, this was a true breakthrough. (We don't use that word lightly on this page.) But instead of a shot that stays with you for year, here you have to take … Continue reading Would you take a pill to prevent AIDS? Those at risk should consider it, says Massachusetts.
The August 22 edition of The New Yorker includes a story by Siddhartha Mukhergee on Dan Barouch, director, Center for Virology and Vaccine Research at BIDMC. He’s on the hunt for a Zika vaccine and his work on HIV is informing the effort. From the article, which is not behind the NYer pay wall: